-
公开(公告)号：US07314619B2
公开(公告)日：2008-01-01
申请号：US10052798
申请日：2001-11-02
CPC分类号： C07K14/4747 , A61K38/00 , C07K14/70578 , C07K16/2878 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/20 , C07K2319/21 , C07K2319/30
摘要： Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
摘要翻译： 提供了能够调节细胞凋亡的新型多肽，称为Apo-2。 还提供了包含Apo-2嵌合体，编码Apo-2的核酸和Apo-2抗体的组合物。
-
公开(公告)号：US08092799B2
公开(公告)日：2012-01-10
申请号：US12859436
申请日：2010-08-19
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28
CPC分类号： C07K14/4747 , A61K38/00 , C07K14/70578 , C07K16/2878 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/20 , C07K2319/21 , C07K2319/30
摘要： Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
摘要翻译： 提供了能够调节细胞凋亡的新型多肽，称为Apo-2。 还提供了包含Apo-2嵌合体，编码Apo-2的核酸和Apo-2抗体的组合物。
-
公开(公告)号：US07807153B2
公开(公告)日：2010-10-05
申请号：US10423448
申请日：2003-04-25
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28
CPC分类号： C07K14/4747 , A61K38/00 , C07K14/70578 , C07K16/2878 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/20 , C07K2319/21 , C07K2319/30
摘要： Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
摘要翻译： 提供了能够调节细胞凋亡的新型多肽，称为Apo-2。 还提供了包含Apo-2嵌合体，编码Apo-2的核酸和Apo-2抗体的组合物。
-
公开(公告)号：US07595046B2
公开(公告)日：2009-09-29
申请号：US11297327
申请日：2005-12-09
CPC分类号： C07K14/4747 , A61K38/00 , C07K14/70578 , C07K16/2878 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/20 , C07K2319/21 , C07K2319/30
摘要： Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
摘要翻译： 提供了能够调节细胞凋亡的新型多肽，称为Apo-2。 还提供了包含Apo-2嵌合体，编码Apo-2的核酸和Apo-2抗体的组合物。
-
公开(公告)号：US20100273257A1
公开(公告)日：2010-10-28
申请号：US12321115
申请日：2009-01-15
申请人： Avi J. Ashkenazi , Kevin P. Baker , Anan Chuntharapai , Austin Gurney , Kyung Jin Kim , William I. Wood
发明人： Avi J. Ashkenazi , Kevin P. Baker , Anan Chuntharapai , Austin Gurney , Kyung Jin Kim , William I. Wood
IPC分类号： C12N5/10 , C07K14/00 , C07K16/18 , C12N5/16 , C07H21/04 , C12N15/63 , C12N1/19 , C12N1/21 , C12N5/071
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/00 , A61K2039/505 , C07K14/4747 , C07K14/70578 , C07K16/2878 , C07K2319/00 , G01N33/57484 , G01N33/68
摘要： Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
摘要翻译： 提供了能够结合Apo-2配体的新型多肽，称为Apo-2DcR。 还提供了包含Apo-2DcR嵌合体，编码Apo-2DcR的核酸和Apo-2DcR抗体的组合物。
-
公开(公告)号：US6046048A
公开(公告)日：2000-04-04
申请号：US780496
申请日：1997-01-08
IPC分类号： C07K14/705 , C07K16/28 , C12N5/16
CPC分类号： C07K14/70575 , C07K16/2875 , C07K2317/34
摘要： A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
摘要翻译： 提供了诱导哺乳动物细胞凋亡的新型细胞因子，称为Apo-2配体。 Apo-2配体被认为是TNF细胞因子家族的成员。 还提供了包括Apo-2配体嵌合体，编码Apo-2配体的核酸和Apo-2配体的抗体的组合物。 进一步提供了使用Apo-2配体诱导细胞凋亡和治疗病理状况如癌症的方法。
-
公开(公告)号：US06359126B1
公开(公告)日：2002-03-19
申请号：US08874837
申请日：1997-06-13
IPC分类号： C07H2104
CPC分类号： C07K16/2848 , A61K38/00 , Y10S530/867
摘要： The invention relates to monoclonal antibodies to the &agr;v&bgr;3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies recognize unique epitopes on &agr;v&bgr;3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
摘要翻译： 本发明涉及已知在破骨细胞表面上大量表达的α受体α整联蛋白受体的单克隆抗体，因此与骨吸收有关。 所公开的单克隆抗体识别出在alphavbeta3上的独特表位，并且可用于治疗与过量骨吸收和/或抑制肿瘤细胞生长相关的病症。
-
公开(公告)号：US5652110A
公开(公告)日：1997-07-29
申请号：US432618
申请日：1995-05-02
IPC分类号： G01N33/53 , A61K38/00 , A61K47/48 , C07K14/705 , C07K16/00 , C07K16/28 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , A61K39/395 , C12N5/00
CPC分类号： C07K16/2848 , A61K38/00 , Y10S530/867
摘要： The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
摘要翻译： 本发明涉及已知在破骨细胞表面上大量表达的αvβ3整联蛋白受体的单克隆抗体，因此与骨吸收有关。 据信所公开的单克隆抗体识别αvβ3上的独特表位，并且可用于治疗与过量骨吸收和/或抑制肿瘤细胞生长相关的病症。
-
公开(公告)号：US07744881B2
公开(公告)日：2010-06-29
申请号：US11819575
申请日：2007-06-28
申请人： Anan Chuntharapai , Kyung Jin Kim
发明人： Anan Chuntharapai , Kyung Jin Kim
IPC分类号： A61K39/395 , C07K14/705 , C07K16/30 , C12N5/18
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2319/30 , G01N2510/00
摘要： Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.
摘要翻译： 提供人类死亡受体4（DR4）抗体。 人类DR4抗体可以包括在药物组合物，制品或试剂盒中。 还提供了使用DR4抗体的治疗和诊断方法。
-
公开(公告)号：US20080171036A1
公开(公告)日：2008-07-17
申请号：US11841802
申请日：2007-08-20
申请人： Anan Chuntharapai , Iqbal Grewal , Kyung Jin Kim , Minhong Yan
发明人： Anan Chuntharapai , Iqbal Grewal , Kyung Jin Kim , Minhong Yan
IPC分类号： A61K39/395 , C12N5/00 , A61P37/00 , A61P35/00 , A61P25/00 , A61P7/00 , A61P13/12 , A61P19/00 , A61K39/44
CPC分类号： C07K16/2878
摘要： TACI receptor antibodies are provided. The TACI antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the TACI antibodies are also provided.
摘要翻译： 提供TACI受体抗体。 TACI抗体可以包括在药物组合物，制品或试剂盒中。 还提供了使用TACI抗体的治疗和诊断方法。
-
-
-
-
-
-
-
-
-
搜索结果
76 条记录 (耗时 0.027 秒)